Miniatura

Fitxers

698883.pdf (950.67 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2019-05-20

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/167964

A four-group urine risk classifier for predicting outcome in prostate cancer patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/bju.14811

Resum

Objectives: to develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of providing diagnostic information of disease status prior to biopsy, and prognostic information for men on active surveillance (AS). Patients and methods: post-digital rectal examination UEV-RNA expression profiles from urine (n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO-based Continuation-Ratio model was built to generate four Prostate-Urine-Risk (PUR) signatures for predicting the probability of normal tissue (PUR-1), D'Amico Low-risk (PUR-2), Intermediate-risk (PUR-3), and High-risk (PUR-4) PCa. This model was applied to a test cohort (n = 177) for diagnostic evaluation, and to an AS sub-cohort (n = 87) for prognostic evaluation. Results: each PUR signature was significantly associated with its corresponding clinical category (p<0.001). PUR-4 status predicted the presence of clinically significant Intermediate or High-risk disease, AUC = 0.77 (95% CI: 0.70-0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub-cohort (n=87), groups defined by PUR status and proportion of PUR-4 had a significant association with time to progression (p<0.001; IQR HR = 2.86, 95% CI:1.83-4.47). PUR-4, when utilised continuously, dichotomised patient groups with differential progression rates of 10% and 60% five years post-urine collection (p<0.001, HR = 8.23, 95% CI:3.26-20.81). Conclusion: UEV-RNA can provide diagnostic information of aggressive PCa prior to biopsy, and prognostic information for men on AS. PUR represents a new & versatile biomarker that could result in substantial alterations to current treatment of PCa patients. This article is protected by copyright. All rights reserved.

Matèries

Indicadors biològics, Biòpsia, Càncer de pròstata, Orina

Matèries (anglès)

Indicators (Biology), Biopsy, Prostate cancer, Urine

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citació

CONNELL, Shea p., HANNA, Marcel, MCCARTHY, Frank, HURST, Rachel, WEBB, Martyn, CURLEY, Helen, WALKER, Helen, MILLS, Robert, BALL, Richard y., SANDA, Martin g., PELLEGRINI, Kathryn l., PATIL, Dattatraya, PERRY, Antoinette s., SCHALKEN, Jack a., PANDHA, Hardev, WHITAKER, Hayley c., DENNIS, Nening, STUTTLE, Christine, MILLS, Ian g., GULDVIK, Ingrid, Movember GAP1 Urine Biomarker Consortium, PARKER, Chris, BREWER, Daniel, COOPER, Colin, CLARK, Jeremy. A four-group urine risk classifier for predicting outcome in prostate cancer patients. _BJU International_. 2019. Vol. 124, núm. 4, pàgs. 609-620. [consulta: 24 de gener de 2026]. ISSN: 1464-4096. [Disponible a: https://hdl.handle.net/2445/167964]

Exportar metadades

JSON - METS

Compartir registre